Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ponatinib
Drug ID BADD_D01799
Description Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Indications and Usage Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Marketing Status approved; investigational
ATC Code L01EA05
DrugBank ID DB08901
KEGG ID D09950
MeSH ID C545373
PubChem ID 24826799
TTD Drug ID D0H0EQ
NDC Product Code Not Available
UNII 4340891KFS
Synonyms ponatinib | 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide | ponatinib hydrochloride | AP24534 | AP-24534 | AP 24534 | Iclusig
Chemical Information
Molecular Formula C29H27F3N6O
CAS Registry Number 943319-70-8
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Moyamoya disease17.08.02.023; 24.01.04.0160.000168%-
Myocardial fibrosis02.04.02.0160.000112%-
Terminal state08.01.03.0790.000112%-
Subclavian artery stenosis24.04.03.0230.000112%-
Blast crisis in myelogenous leukaemia01.10.08.002; 16.01.08.0020.001063%-
Secondary immunodeficiency10.03.03.0090.000112%-
Leukaemia recurrent01.10.03.005; 16.01.03.0050.000392%-
Acute lymphocytic leukaemia recurrent01.10.01.003; 16.01.01.0030.001623%-
Graft versus host disease in skin10.02.01.062; 12.02.09.031; 23.07.04.0250.000280%-
Central nervous system leukaemia01.10.03.004; 16.01.03.004; 17.02.10.0190.000280%-
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.000112%-
Carotid arteriosclerosis17.08.02.015; 24.04.06.0310.000224%-
Chronic myeloid leukaemia transformation01.10.07.004; 16.01.07.0040.000448%-
Chronic myeloid leukaemia recurrent01.10.07.003; 16.01.07.0030.000560%-
Graft versus host disease in gastrointestinal tract07.11.01.027; 10.02.01.059; 12.02.09.0280.000168%-
Dilated cardiomyopathy02.04.01.0170.000168%-
Disease complication08.01.03.0870.000336%-
Gait inability08.01.02.011; 17.02.05.0690.000168%-
Graves' disease05.02.02.009; 06.09.04.009; 10.04.08.0140.000112%-
Myelosuppression01.03.03.0150.000504%-
Philadelphia positive acute lymphocytic leukaemia01.10.01.006; 16.01.01.0060.000280%-
Superficial vein thrombosis24.01.02.0160.000112%-
Therapy non-responder08.06.01.0630.000728%-
Treatment noncompliance08.06.01.067; 12.09.02.0060.000504%-
The 13th Page    First    Pre   13    Total 13 Pages